IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$76.48 USD
+1.62 (2.16%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $76.46 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ITCI 76.48 +1.62(2.16%)
Will ITCI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITCI
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
ITCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Other News for ITCI
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Intra-Cellular price target raised by $6 at Needham, here's why
A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
Buy Rating Affirmed for Intra-Cellular Therapies with Caplyta Poised for Blockbuster Success
Intra-Cellular just downgraded at UBS, here's why